ProCE Banner Activity

Dacomitinib vs Gefitinib in Advanced NSCLC With EGFR-Activating Mutations: Final OS Analysis From the Phase III ARCHER 1050 Trial

Slideset Download
Conference Coverage
In patients with advanced EGFR mutation–positive NSCLC, first-line dacomitinib significantly improved OS vs gefitinib by 7.3 months with a 24% reduced risk of death.

Released: June 12, 2018

Expiration: June 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen